While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers continues to grow, especially in the research and development (R&D) field, offering some resilience in times of geopolitical and economic disruptions.
One such emerging technology, artificial intelligence (AI), is expected to play an important role in the pharmaceutical sector in 2023. According to survey data published in GlobalData’s The State of the Biopharmaceutical Industry – 2023 report, 39% of surveyed healthcare industry professionals believed that AI would trend as the most disruptive emerging technology in the sector during this year.
With successful AI use cases increasing, the industry has been gaining trust in emerging technologies. Recent cases in the pharmaceutical sector include Poolbeg Pharma finding more than one respiratory syncytial virus (RSV) vaccine candidate with AI by going through a vast amount of early stage clinical data to prioritise candidates and reposition them as novel treatments for RSV infection.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.